CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Published in
Clinical Lymphoma, Myeloma & Leukemia, October 2022
Pharmacology, Toxicology and Pharmaceutical Science
3
12%
Unspecified
2
8%
Medicine and Dentistry
2
8%
Arts and Humanities
1
4%
Chemical Engineering
1
4%
Other
6
24%
Unknown
10
40%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 November 2022.
All research outputs
#6,823,262
of 34,560,275 outputs
Outputs from Clinical Lymphoma, Myeloma & Leukemia
#418
of 2,715 outputs
Outputs of similar age
#100,731
of 465,921 outputs
Outputs of similar age from Clinical Lymphoma, Myeloma & Leukemia
#11
of 243 outputs
Altmetric has tracked 34,560,275 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,715 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 465,921 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 243 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.
